EA
ALXN

Euclid Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Euclid Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,160
Closed -$602K – 493
2016
Q2 		$602K Sell
5,160
-2,437
-32% -$346K 0.03% 365
2016
Q1 		$1.06M Sell
7,597
-12,227
-62% -$1.8M 0.04% 332
2015
Q4 		$3.78M Buy
+19,824
New +$3.46M 0.12% 217
2015
Q3 		– Sell
-33,347
Closed -$6.03M – 460
2015
Q2 		$6.03M Sell
33,347
-39,963
-55% -$6.9M 0.12% 220
2015
Q1 		$12.7M Buy
+73,310
New +$13.3M 0.23% 90
2014
Q4 		– Sell
-100,840
Closed -$16.7M – 520
2014
Q3 		$16.7M Buy
100,840
+6,160
+7% +$1.01M 0.12% 166
2014
Q2 		$14.8M Sell
94,680
-14,514
-13% -$2.29M 0.1% 197
2014
Q1 		$16.6M Buy
109,194
+31,010
+40% +$4.93M 0.13% 160
2013
Q4 		$10.4M Sell
78,184
-3,656
-4% -$439K 0.09% 226
2013
Q3 		$9.51M Buy
81,840
+16,674
+26% +$1.83M 0.1% 207
2013
Q2 		$6.01M Buy
+65,166
New +$6.28M 0.08% 265

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Euclid Advisors's ALXN Position: Q3 2016 in Review

Euclid Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 5,160 shares — an estimated $602K sold.

Euclid Advisors first reported a position in ALXN in Q2 2013 and held it in 11 quarters. The position peaked at $16.7M in Q3 2014. 518 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Euclid Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Euclid Advisors sold 5,160 Alexion Pharmaceuticals shares in Q3 2016, an estimated $602K.
  • Euclid Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Euclid Advisors's Alexion Pharmaceuticals position peaked at $16.7M in Q3 2014.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.